RET-MAP:携带RET融合的肺癌患者临床生物学特征与治疗反应的国际多中心研究
这项回顾性多中心研究纳入31个癌症中心的218例RET阳性非小细胞肺癌患者,评估手术、化疗、免疫检查点抑制剂、多靶点酪氨酸激酶抑制剂及RET抑制剂的治疗结局。RET抑制剂组客观缓解率76%、中位无进展生存16.2个月,中位总生存50.6个月优于未用RET抑制剂组的16.3个月(p<0.0001)。
要点
- RET阳性NSCLC以腺癌为主(93%),最常见融合伴侣为KIF5B(72%),常见转移部位为肺(50%)、骨(43%)和胸膜(40%)。
- RET抑制剂组客观缓解率76%、中位无进展生存16.2个月;铂类双药化疗组分别为55%和8.7个月。
- RET抑制剂组中位总生存50.6个月,未用RET抑制剂组16.3个月(p<0.0001)。
核心结论
- RET阳性NSCLC患者主要累及胸部与骨,肿瘤突变负荷和程序性死亡配体1表达均较低。
- RET抑制剂显著改善生存,而免疫检查点抑制剂可能在部分选定患者中有活性。
研究设计与样本
- 回顾性多中心研究,纳入31个癌症中心任何分期的RET阳性NSCLC患者。
- 纳入2012年2月至2022年4月期间的218例患者。
- 分子检测包括DNA/RNA测序或荧光原位杂交分析。
- 评估手术、化疗、免疫检查点抑制剂、化疗联合免疫检查点抑制剂、多靶点酪氨酸激酶抑制剂和RET抑制剂的临床生物学特征与治疗结局(按研究者评估)。
主要发现
- 218例患者中位年龄63岁,女性占56%,腺癌占93%,吸烟者占41%。
- 最常见融合伴侣为KIF5B(72%);中位肿瘤突变负荷为2.5(范围1-4)个突变/兆碱基,中位程序性死亡配体1表达为10%(范围0%-55%)。
- 最常见转移部位为肺(50%)、骨(43%)和胸膜(40%);晚期NSCLC诊断时中枢神经系统转移占21%,末次随访或死亡时占31%。
- 客观缓解率与中位无进展生存:铂类双药化疗55%和8.7个月,单药化疗26%和3.6个月,化疗联合免疫检查点抑制剂46%和9.6个月,免疫检查点抑制剂23%和3.1个月,多靶点酪氨酸激酶抑制剂37%和3个月,RET抑制剂76%和16.2个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Nearly 1% to 2% of NSCLCs harbor RET fusions. Characterization of this rare population is still incomplete. METHODS: This retrospective multicenter study included patients with any-stage RET positive (RET+) NSCLC from 31 cancer centers. Molecular profiling included DNA/RNA sequencing or fluorescence in situ hybridization analyses. Clinicobiological features and treatment outcomes (per investigator) with surgery, chemotherapy (CT), immune checkpoint blockers (ICBs), CT-ICB, multityrosine kinase inhibitors, and RET inhibitors (RETis) were evaluated. RESULTS: For 218 patients included between February 2012 and April 2022, median age was 63 years, 56% were females, 93% had adenocarcinoma, and 41% were smokers. The most frequent fusion partner was KIF5B (72%). Median tumor mutational burden was 2.5 (range: 1-4) mutations per megabase, and median programmed death-ligand 1 expression was 10% (range: 0%-55%). The most common metastatic sites were the lung (50%), bone (43%), and pleura (40%). Central nervous system metastases were found at diagnosis of advanced NSCLC in 21% of the patients and at last follow-up or death in 31%. Overall response rate and median progression-free survival were 55% and 8.7 months with platinum doublet, 26% and 3.6 months with single-agent CT, 46% and 9.6 months with CT-ICB, 23% and 3.1 months with ICB, 37% and 3 months with multityrosine kinase inhibitor, and 76% and 16.2 months with RETi, respectively. Median overall survival was longer in patients treated with RETi versus no RETi (50.6 mo [37.7-72.1] versus 16.3 mo [12.7-28.8], p < 0.0001). CONCLUSIONS: Patients with RET+ NSCLC have mainly thoracic and bone disease and low tumor mutational burden and programmed death-ligand 1 expression. RETi markedly improved survival, whereas ICB may be active in selected patients.
引用
- Aldea M, Marinello A, Duruisseaux M, et al. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. J Thorac Oncol. 2023. PMID: 36646211. doi:10.1016/j.jtho.2022.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。